PRL3-zumab for advanced age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a new injectable medicine called PRL3-zumab for patients with advanced wet macular degeneration (nAMD) whose condition hasn't improved enough with standard treatments. The goal is to see if this new approach can help preserve or improve vision in people who have already tried at least two other eye injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with wet age-related macular degeneration (nAMD) affecting your central vision
- You have already tried at least two standard eye injection treatments (like Ranibizumab, Aflibercept, or Faricimab) without adequate improvement
- Your vision loss is primarily caused by nAMD, not another eye condition
- You can stop your current eye injection treatment for a 'washout period' (typically 4–8 weeks, depending on which drug you're taking) before starting the trial
- Your eye shows specific signs of active disease on imaging: fluid accumulation, swelling, or leakage in the central area of the retina
- Your general health labs (blood counts, kidney and liver function) are normal or near-normal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This study tests a new medicine given as an eye injection to treat wet age-related macular degeneration (AMD), a condition that causes blurry or lost vision. The treatment aims to improve vision by targeting abnormal blood vessels in the eye.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.